242 related articles for article (PubMed ID: 37591251)
1. Identification of KLHDC2 as an efficient proximity-induced degrader of K-RAS, STK33, β-catenin, and FoxP3.
Röth S; Kocaturk NM; Sathyamurthi PS; Carton B; Watt M; Macartney TJ; Chan KH; Isidro-Llobet A; Konopacka A; Queisser MA; Sapkota GP
Cell Chem Biol; 2023 Oct; 30(10):1261-1276.e7. PubMed ID: 37591251
[TBL] [Abstract][Full Text] [Related]
2. Co-opting the E3 ligase KLHDC2 for targeted protein degradation by small molecules.
Hickey CM; Digianantonio KM; Zimmermann K; Harbin A; Quinn C; Patel A; Gareiss P; Chapman A; Tiberi B; Dobrodziej J; Corradi J; Cacace AM; Langley DR; Békés M
Nat Struct Mol Biol; 2024 Feb; 31(2):311-322. PubMed ID: 38177675
[TBL] [Abstract][Full Text] [Related]
3. Targeted kinase degradation via the KLHDC2 ubiquitin E3 ligase.
Kim Y; Seo P; Jeon E; You I; Hwang K; Kim N; Tse J; Bae J; Choi HS; Hinshaw SM; Gray NS; Sim T
Cell Chem Biol; 2023 Nov; 30(11):1414-1420.e5. PubMed ID: 37567174
[TBL] [Abstract][Full Text] [Related]
4. Ligandability of E3 Ligases for Targeted Protein Degradation Applications.
Belcher BP; Ward CC; Nomura DK
Biochemistry; 2023 Feb; 62(3):588-600. PubMed ID: 34473924
[TBL] [Abstract][Full Text] [Related]
5. PROTACs: A novel strategy for cancer drug discovery and development.
Han X; Sun Y
MedComm (2020); 2023 Jun; 4(3):e290. PubMed ID: 37261210
[TBL] [Abstract][Full Text] [Related]
6. Expanding the ligand spaces for E3 ligases for the design of protein degraders.
Shah Zaib Saleem R; Schwalm MP; Knapp S
Bioorg Med Chem; 2024 May; 105():117718. PubMed ID: 38621319
[TBL] [Abstract][Full Text] [Related]
7. Harnessing nanobodies for target protein degradation through the Affinity-directed PROtein Missile (AdPROM) system.
Carton B; Röth S; Macartney TJ; Sapkota GP
Methods Enzymol; 2023; 681():61-79. PubMed ID: 36764764
[TBL] [Abstract][Full Text] [Related]
8. Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders.
Setia N; Almuqdadi HTA; Abid M
Eur J Med Chem; 2024 Feb; 265():116041. PubMed ID: 38199162
[TBL] [Abstract][Full Text] [Related]
9. High throughput E3 ligase degron binding assays for novel PROTAC ligand discovery.
Guenette RG; Potts PR
Methods Enzymol; 2023; 681():23-39. PubMed ID: 36764759
[TBL] [Abstract][Full Text] [Related]
10. Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets.
Xiong Y; Zhong Y; Yim H; Yang X; Park KS; Xie L; Poulikakos PI; Han X; Xiong Y; Chen X; Liu J; Jin J
J Am Chem Soc; 2022 Dec; 144(49):22622-22632. PubMed ID: 36448571
[TBL] [Abstract][Full Text] [Related]
11. A synthetic KLHL20 ligand to validate CUL3
Farrell BM; Gerth F; Yang CR; Yeh JT
Genes Dev; 2022 Sep; 36(17-18):1031-1042. PubMed ID: 36328355
[TBL] [Abstract][Full Text] [Related]
12. A Phenotypic Approach for the Identification of New Molecules for Targeted Protein Degradation Applications.
Stacey P; Lithgow H; Lewell X; Konopacka A; Besley S; Green G; Whatling R; Law R; Röth S; Sapkota GP; Smith IED; Burley GA; Harling J; Benowitz AB; Queisser MA; Muelbaier M
SLAS Discov; 2021 Aug; 26(7):885-895. PubMed ID: 34041938
[TBL] [Abstract][Full Text] [Related]
13. Discovery of E3 Ligase Ligands for Target Protein Degradation.
Lee J; Lee Y; Jung YM; Park JH; Yoo HS; Park J
Molecules; 2022 Oct; 27(19):. PubMed ID: 36235052
[TBL] [Abstract][Full Text] [Related]
14. Modeling the CRL4A ligase complex to predict target protein ubiquitination induced by cereblon-recruiting PROTACs.
Bai N; Riching KM; Makaju A; Wu H; Acker TM; Ou SC; Zhang Y; Shen X; Bulloch DN; Rui H; Gibson BW; Daniels DL; Urh M; Rock BM; Humphreys SC
J Biol Chem; 2022 Apr; 298(4):101653. PubMed ID: 35101445
[TBL] [Abstract][Full Text] [Related]
15. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
[TBL] [Abstract][Full Text] [Related]
16. Target protein localization and its impact on PROTAC-mediated degradation.
Simpson LM; Glennie L; Brewer A; Zhao JF; Crooks J; Shpiro N; Sapkota GP
Cell Chem Biol; 2022 Oct; 29(10):1482-1504.e7. PubMed ID: 36075213
[TBL] [Abstract][Full Text] [Related]
17. PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery.
Gu S; Cui D; Chen X; Xiong X; Zhao Y
Bioessays; 2018 Apr; 40(4):e1700247. PubMed ID: 29473971
[TBL] [Abstract][Full Text] [Related]
18. DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance.
Schröder M; Renatus M; Liang X; Meili F; Zoller T; Ferrand S; Gauter F; Li X; Sigoillot F; Gleim S; Stachyra TM; Thomas JR; Begue D; Khoshouei M; Lefeuvre P; Andraos-Rey R; Chung B; Ma R; Pinch B; Hofmann A; Schirle M; Schmiedeberg N; Imbach P; Gorses D; Calkins K; Bauer-Probst B; Maschlej M; Niederst M; Maher R; Henault M; Alford J; Ahrne E; Tordella L; Hollingworth G; Thomä NH; Vulpetti A; Radimerski T; Holzer P; Carbonneau S; Thoma CR
Nat Commun; 2024 Jan; 15(1):275. PubMed ID: 38177131
[TBL] [Abstract][Full Text] [Related]
19. Clinical Translation of Targeted Protein Degraders.
Kong NR; Jones LH
Clin Pharmacol Ther; 2023 Sep; 114(3):558-568. PubMed ID: 37399310
[TBL] [Abstract][Full Text] [Related]
20. Bifunctional Peptide Nanofibrils for Targeted Protein Degradation.
Lin Z; Garcia BA; Lv D
Angew Chem Int Ed Engl; 2024 Jan; 63(3):e202316581. PubMed ID: 38059785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
